ஷோனன் காமகுரா ஜநரல் மருத்துவமனை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from ஷோனன் காமகுரா ஜநரல் மருத்துவமனை. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In ஷோனன் காமகுரா ஜநரல் மருத்துவமனை Today - Breaking & Trending Today

Elixir Medical Corporation: Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System

Elixir Medical Corporation: Elixir Medical Expands BIOADAPTOR Randomized Controlled Trial of DynamX Coronary Bioadaptor System
Elixir Medical, a developer of innovative, drug-eluting cardiovascular devices, today announced that the BIOADAPTOR randomized controlled trial (RCT) is expanding to centers in Belgium and Germany. The BIOADAPTOR RCT is evaluating the DynamX Coronary Bioadaptor System, the first drug-eluting coronary artery implant that adapts to vessel physiology.
The BIOADAPTOR RCT is a multicenter, randomized, single-blind study enrolling 444 patients from 30 centers in Europe and Japan treated with the DynamX Bioadaptor in a 1:1 randomization to Resolute Onyx, a leading drug-eluting stent (DES). The primary endpoint of the study is target lesion failure at one year. Secondary endpoints include measures of the implants ability to accommodate vessel growth from disease progression and restore artery pulsatility in an imaging subset, as well as other major c ....

United States , Coll Cardiol , Michelle Mcadam , Kostenloser Wertpapierhandel , Shigeru Saito , Stefan Verheye , Austrian Wiktor Stent Study Group , Antwerp Cardiovascular Centre , Elixir Medical Corporation , Catheterization Laboratory At Shonan Kamakura , Chronic Communications Inc , Elixir Medical , Dynamx Coronary Bioadaptor System , Dynamx Bioadaptor , Resolute Onyx , Catheterization Laboratory , Shonan Kamakura General Hospital , Antwerp Cardiovascular , Medical Corporation , Varying Outcomes With , Absorb Bioresorbable Vascular Scaffold During , Year Follow Up , Systematic Meta Analysis , Individual Patient Data Pooled , Randomized Controlled Trial , Paclitaxel Eluting Stents ,

First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology

First Patient Treated in Elixer Dynamx Coronary Bioadaptor Stent Technology
International trial compares Bioadaptor coronary stent designed to adapt to vessel physiology with stanard DES
The Elixer Dynamx Coronary Bioadaptor Stent technology uses a bioresorbable polymer that dissolves after three months and disconnected joints between numerous stent segments, allowing it to articulate and shape to the vessel and its movement.
April, 14, 2021 – Elixir Medical recently announced the first patient was treated in the BIOADAPTOR randomized controlled trial (RCT) of the DynamX Coronary Bioadaptor System, the first drug-eluting coronary stent that adapts to vessel physiology. It uses a drug-eluting bioresorbable polymer coating that dissolves after three months, which disconnects joints between segments of the metallic stent, allowing it to articulate with vessel movement and its natural shape. ....

United States , Motasim Sirhan , Shigeru Saito , Shonan Kamakura , Elixir Medical Corporation , Elixir Medical , Dynamx Coronary Bioadaptor System , Shonan Kamakura General Hospital , Dynamx Bioadaptor , Medtronic Resolute Onyx , Holger Nef , Elixer Dynamx Coronary Bioadaptor Stent , Medical Corporation , ஒன்றுபட்டது மாநிலங்களில் , ஶிகேரு சைட்டோ , ஷோனன் காமகுரா , அமுதம் மருத்துவ நிறுவனம் , அமுதம் மருத்துவ , ஷோனன் காமகுரா ஜநரல் மருத்துவமனை , மெதிடிறோனிக் உறுதியானது ஓனிக்ஸ் , ஹோல்கர் நெப் , மருத்துவ நிறுவனம் ,